LTRNLantern Pharma Inc.

Nasdaq lanternpharma.com


$ 4.53 $ -0.30 (-6.21 %)    

Thursday, 18-Jul-2024 15:57:41 EDT
QQQ $ 480.70 $ -4.80 (-0.99 %)
DIA $ 406.94 $ -4.99 (-1.21 %)
SPY $ 552.84 $ -4.10 (-0.74 %)
TLT $ 93.46 $ -0.73 (-0.78 %)
GLD $ 225.79 $ -1.44 (-0.63 %)
$ 4.48
$ 4.70
$ 0.00 x 0
$ 0.00 x 0
$ 4.43 - $ 4.70
$ 2.38 - $ 11.99
64,562
na
51.89M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-20-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-01-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 05-03-2021 03-31-2021 10-Q
14 03-10-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lantern-pharma-achieves-milestone-towards-development-of-molecular-diagnostic-for-use-in-oncology-clinical-trials-for-patient-selection-and-stratification-with-drug-candidate-lp-184--confirmed-ptgr1-as-a-key-biomarker-that-it-intends-to-use-to-optimize-patient-selection-based-on-potential-tumor-sensitivity-to-the-drug-candidate-lp-184

Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine le...

 lantern-pharma-q1-2024-gaap-eps-051-misses-043-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....

 oregon-therapeutics--lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853--a-potent-inhibitor-of-cancer-metabolism

Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, toda...

 hc-wainwright--co-reiterates-neutral-on-lantern-pharma

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.

 lantern-pharma-approved-to-expand-harmonic-clinical-trial-for-non-small-cell-lung-cancer-in-never-smokers-into-japan-and-taiwan

never smokers – a growing and unaddressed patient population.Dr. Yashushi Goto a leading lung cancer clinician-scientist at the...

 recap-lantern-pharma-q4-earnings
Recap: Lantern Pharma Q4 Earnings
03/18/2024 20:30:21

 lantern-pharma-q4-2023-gaap-eps-039-beats-048-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.48...

 earnings-scheduled-for-march-18-2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

 lantern-pharma-earnings-preview
Lantern Pharma Earnings Preview
03/15/2024 15:00:52